Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and
Latest Announcements
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
29 Dec 2020 | Read More
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe.
23 Dec 2020 | Read More
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg
21 Dec 2020 | Read More
Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets,1 mg and 5 mg
1 Dec 2020 | Read More
Glenmark to divest select Anti-Allergy brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its ‘Ryaltris’ Launch
28 Nov 2020 | Read More
Credit Rating by S&P Global Ratings
25 Nov 2020 | Read More
Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure
23 Nov 2020 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg
11 Nov 2020 | Read More
Newspaper Publication of Q2 FY 2020-21 Result
9 Nov 2020 | Read More
Glenmark’s consolidated revenue increased by 4.88 % to Rs. 29,524.79 mn for Q2 FY 2020-21
6 Nov 2020 | Read More
Glenmark’s MDA Q2 FY 2020 – 21
6 Nov 2020 | Read More
Glenmark’s Q2 FY 2020-21 Results
6 Nov 2020 | Read More
Board Meeting Newspaper Advertisement – November 6, 2020
29 Oct 2020 | Read More
Q2 FY21 Earnings Call Invitation – November 9, 2020
28 Oct 2020 | Read More
Board Meeting Intimation – 6th November, 2020
27 Oct 2020 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg
19 Oct 2020 | Read More
Glenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India
14 Oct 2020 | Read More
Glenmark announces results of its “FAITH” combination trial
14 Oct 2020 | Read More
Transcript of the 42nd AGM
5 Oct 2020 | Read More
Proceedings and Scrutinizer's Report of the 42nd AGM
30 Sep 2020 | Read More
Chairman’s Speech at the 42nd AGM
30 Sep 2020 | Read More
42nd AGM Notice – Newspaper Advertisement
7 Sep 2020 | Read More
Newspaper Advertisement of 42nd Annual General Meeting
4 Sep 2020 | Read More
Glenmark AGM Notice 2020
4 Sep 2020 | Read More
Newspaper Publication of Q1 FY 2020-21 Result
17 Aug 2020 | Read More
Glenmark’s consolidated revenue grew by 0.94 % at Rs. 23,447.87 Mn. for Q1 FY 2020-21
14 Aug 2020 | Read More
Glenmark’s MDA Q1 FY 2020 – 21
14 Aug 2020 | Read More
Glenmark’s Q1 FY 2020-21 Results
14 Aug 2020 | Read More
Board Meeting Newspaper Advertisement – 14th August, 2020
7 Aug 2020 | Read More
Board Meeting Intimation – 14th August, 2020
6 Aug 2020 | Read More
Q1 FY21 Earnings Call Invitation – August 17, 2020
6 Aug 2020 | Read More
Credit Rating by Fitch Ratings
13 Jul 2020 | Read More
Notice to Shareholders for transfer of shares to IEPF
2 Jul 2020 | Read More
Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20
26 Jun 2020 | Read More
Glenmark’s MDA Q4 FY 2019 – 20
26 Jun 2020 | Read More
Glenmark’s Q4 FY 2019-20 Results
26 Jun 2020 | Read More
Board Meeting Intimation – 26th June, 2020
19 Jun 2020 | Read More
Q4 FY20 Earnings Call Invitation – June 29, 2020
17 Jun 2020 | Read More
Board Meeting Intimation – 26th June, 2020
17 Jun 2020 | Read More
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India
12 May 2020 | Read More
Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function
11 May 2020 | Read More
Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients
30 Apr 2020 | Read More
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg
29 Apr 2020 | Read More
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg
23 Mar 2020 | Read More
Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever
23 Mar 2020 | Read More
Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
27 Feb 2020 | Read More
Newspaper Publication of Q3 FY 2019-20 Result
17 Feb 2020 | Read More
Glenmark’s consolidated revenue rises by 7.07% to Rs. 27,355.61 Mn. in Q3 FY 2019-20
14 Feb 2020 | Read More
Glenmark’s MDA Q3 FY 2019 – 20
14 Feb 2020 | Read More
Glenmark’s Q3 FY 2019-20 Results
14 Feb 2020 | Read More
Q3 FY20 Earnings Call Invitation – February 17, 2020
4 Feb 2020 | Read More
BM Notice Newspaper Publication – 14th February, 2020
3 Feb 2020 | Read More
Notice of Board Meeting - 31st January, 2020
31 Jan 2020 | Read More
Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia
20 Dec 2019 | Read More
Certificate of Compliance issued by the European regulator, SUKL, Czech Republic for Glenmark’s Baddi manufacturing facility
16 Dec 2019 | Read More
Newspaper Publication of Q2 FY 2019-20
19 Nov 2019 | Read More
Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
14 Nov 2019 | Read More
Glenmark’s MDA Q2 FY 2019 – 20
14 Nov 2019 | Read More
Glenmark’s Q2 FY 2019-20 Results
14 Nov 2019 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%
11 Nov 2019 | Read More
Q2 FY20 Earnings Concall Invitation - November 15, 2019
7 Nov 2019 | Read More
BM Notice Newspaper Publication – 14th November, 2019
6 Nov 2019 | Read More
Notice of Board Meeting - 14th November, 2019
5 Nov 2019 | Read More
Proceedings and Scrutinizer's Report of the 41st AGM
28 Sep 2020 | Read More
Newspaper Publication of Annual General Meeting Notice
5 Sep 2019 | Read More
Glenmark AGM Notice 2019
3 Sep 2019 | Read More
AGM Intimation to the Exchange
25 Aug 2019 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)
23 Aug 2019 | Read More
Glenmark’s MDA Q1 FY 2019 – 20
13 Aug 2019 | Read More
Glenmark’s Q1 FY 2019-20 Results
13 Aug 2019 | Read More
Glenmark’s consolidated revenue at Rs. 23,228.79 Mn. for Q1 FY 2019 – 20
13 Aug 2019 | Read More
Glenmark Q1 FY 2019 – 20 Results Earnings Call
5 Aug 2019 | Read More
BM Notice Newspaper Publication – 13th August, 2019
1 Aug 2019 | Read More
Notice of Board Meeting - 13th August, 2019
31 Jul 2019 | Read More
Credit Rating by Fitch Ratings
11 Jul 2019 | Read More
Newspaper Publication - Notice to Shareholder for transfer of shares to IEPF
26 Jun 2019 | Read More
FDA Issues Complete Response Letter for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg])
22 Jun 2019 | Read More
Newspaper Publication of Q4 Results
31 May 2019 | Read More
Glenmark’s consolidated revenue rises 12.44% to Rs. 25,634.74 Mn. for Q4 FY 2018-19
29 May 2019 | Read More
Glenmark’s MDA Q4 FY 2018 – 19
29 May 2019 | Read More
Glenmark’s Q4 FY 2018-19 Results
29 May 2019 | Read More
BM Notice Newspaper Publication – 29th May, 2019
22 May 2019 | Read More
Glenmark Q4 FY 2018 - 19 Results Earnings Call
21 May 2019 | Read More
Board Meeting Intimation – 29th May, 2019
14 May 2019 | Read More
Newspaper Publication of Q3 Results
18 Feb 2019 | Read More
Glenmark’s Q3 FY 2018-19 Results
14 Feb 2019 | Read More
Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
14 Feb 2019 | Read More
Glenmark’s MDA Q3 FY 2018 – 19
14 Feb 2019 | Read More
BM Newspaper Publication – 14th February, 2019
4 Feb 2019 | Read More
Glenmark Q3 FY 2018 - 19 Results Earnings Call
4 Feb 2019 | Read More
Board Meeting Intimation – 14th February, 2019
1 Feb 2019 | Read More
J P Morgan Healthcare Conference 2019 I Presentation
8 Jan 2019 | Read More
Newspaper Publication of Q2 Results
23 Nov 2018 | Read More
Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018 – 19
13 Nov 2018 | Read More
Glenmark’s MDA Q2 FY 2018 – 19
13 Nov 2018 | Read More
Glenmark’s Q2 FY 2018-19 Results
13 Nov 2018 | Read More
BM Newspaper Publication
5 Nov 2018 | Read More
Board Meeting Notice November 13, 2018
2 Nov 2018 | Read More
Announcement of Results of the Repurchase
3 Oct 2018 | Read More
Newspaper Publication of Annual General Meeting Notice
28 Sep 2018 | Read More
AGM Intimation to the exchange
21 Aug 2018 | Read More
Newspaper Publication of Q1 Results
19 Aug 2018 | Read More
Glenmark’s consolidated revenue at Rs. 21,656.17 Mn. for Q1 FY 2018 – 19
10 Aug 2018 | Read More
Glenmark’s Q1 FY 2018-19 Results
10 Aug 2018 | Read More
Glenmark’s MDA Q1 FY 2018 – 19
10 Aug 2018 | Read More
Q1 FY19 Earnings Concall Invitation - Aug 13, 2018
3 Aug 2018 | Read More
Glenmark BM Notice Navshakti
31 Jul 2018 | Read More
Glenmark BM Notice FPJ
31 Jul 2018 | Read More
IEPF – Notice to Shareholders
29 Jun 2018 | Read More
Newspaper Publication of Q4/Annual Results - Loksatta
6 Jun 2018 | Read More
Newspaper Publication of Q4/Annual Results
5 Jun 2018 | Read More
Glenmark’s consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017 – 18
29 May 2018 | Read More
Glenmark’s MDA Q4 FY 18
29 May 2018 | Read More
Glenmark’s Q4 FY18 Results
29 May 2018 | Read More
Q4 Earnings Concall Invitation
28 May 2018 | Read More
Glenmark BM Notice Navshakti
17 May 2018 | Read More
Glenmark BM Notice FPJ
17 May 2018 | Read More
Newspaper Publication of Q3 Results
9 Feb 2018 | Read More
AGM Notice Announcement
8 Sep 2017 | Read More
Board Meeting Notice July 27, 2017
14 Jul 2017 | Read More
Glenmark FPJ Page 10
14 Jul 2017 | Read More
Glenmark Navshakti Page 8
14 Jul 2017 | Read More
Glenmark Pharmaceuticals Receives Tentative ANDA Approval For Solifenacin Succinate Tablets, 5 mg and 10 mg
22 Jun 2017 | Read More
Glenmark's consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 -- 17
11 May 2017 | Read More
Q4 FY 2017 Results sheet & Statement of Assets and Liabilities
11 May 2017 | Read More
Q4 FY 2017 Management Discussions and Analysis
11 May 2017 | Read More
Q4 Earnings Concall Invitation May 12, 2017
8 May 2017 | Read More
The Free Press Journal
5 May 2017 | Read More
Navshakti
5 May 2017 | Read More
Intimation regarding NSE board meeting
3 May 2017 | Read More
Statement on Form 483 at the Ankleshwar API plant
20 Feb 2017 | Read More
Glenmark’s Q3 FY 17 results
2 Feb 2017 | Read More
Glenmark’s MDA Q3 FY 17
2 Feb 2017 | Read More
Glenmark’s consolidated revenue increases by 42.55 % to Rs. 25,350.08 Mn for Q3 FY 2016 – 17
2 Feb 2017 | Read More
J P Morgan Healthcare Conference – presentation
30 Jan 2017 | Read More
Intimation regarding board meeting
17 Jan 2017 | Read More
Statement of Investor Complaints for Q3 (F. Y. 2016-17)
11 Jan 2016 | Read More
Webcast of analyst and investor meet 2016
29 Dec 2016 | Read More
Strategic Blueprint for the Next Decade – Investor presentation
19 Dec 2016 | Read More
Strategic Blueprint for the Next Decade – Media presentation
19 Dec 2016 | Read More
Glenmark's Q2 FY17 Result Balance Sheet
2 Nov 2016 | Read More
Glenmark's MDA Q2 FY 2017
2 Nov 2016 | Read More
Glenmark’s consolidated revenue increases by 16.48% to Rs. 22241.09 Mn for Q2 FY 2016 – 17
2 Nov 2016 | Read More
Statement of Investor Complaints for Q2
10 Oct 2016 | Read More
Shareholding Pattern for Q2
10 Oct 2016 | Read More
Corporate Governance Report for Q2
10 Oct 2016 | Read More
Reconciliation of Share Capital Audit Report
10 Oct 2016 | Read More
Compliance Certificate under Regulation 7(3)
10 Oct 2016 | Read More
Certificate from Practicing Company Secretary under Regulation 40(9)
10 Oct 2016 | Read More
38th AGM Proceedings
12 Aug 2016 | Read More
38th AGM Notice – The Free Press Journal
21 Jul 2016 | Read More
38th AGM Notice – Navshakti
21 Jul 2016 | Read More
Glenmark e-voting notice
19 Jul 2016 | Read More
Glenmark notice proxy form
19 Jul 2016 | Read More
Annual report FY 2016
19 Jul 2016 | Read More
Intimation to the exchange
18 Jul 2016 | Read More
Statement of Investor Complaint
13 Jul 2016 | Read More
Reconciliation Share Capital
30 Jun 2016 | Read More
Q4 Shareholding Pattern
30 Jun 2016 | Read More
Corporate governance website
30 Jun 2016 | Read More
Approval of Subscription Agreement for FCCB's
31 May 2016 | Read More
Launch of FCCB's
31 May 2016 | Read More
Q4 - Statement of Investor Complaints
7 Apr 2016 | Read More
Q4 - Reconciliation Share Capital
31 Mar 2016 | Read More
Q4 - Format of Holding of specified securities (2)
31 Mar 2016 | Read More
Q4 - Format of Holding of specified securities
31 Mar 2016 | Read More
Authorised KMP for Disclosure of Materality of Events or Information
28 Jan 2016 | Read More
Cancellations of ESOP Options
28 Jan 2016 | Read More
Glenmark JPMorgan 2016
15 Jan 2016 | Read More

About Us
Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier futureContact Us
For shareholder queries, please email to
complianceofficer@glenmarkpharma.com